Enclomiphene pros and cons: the honest tradeoffs

Last updated 2026-07-30

What exactly is enclomiphene, and how is it different from clomiphene?

Clomiphene citrate is actually a mixture of two mirror-image molecules: enclomiphene and zuclomiphene. When your doctor's father's generation prescribed Clomid for male hypogonadism (off-label, since Clomid is FDA-approved only for female infertility), patients got both isomers in roughly equal parts ^[1]. Enclomiphene is the trans-isomer, the one that actually does the useful work in men. It blocks estrogen receptors at the hypothalamus, which tricks your brain into thinking estrogen is low. Your hypothalamus responds by pumping out more GnRH, which drives the pituitary to release more LH and FSH, which drives the testes to make more testosterone and sperm ^[1]. Zuclomiphene, the other isomer, has a much longer half-life (it lingers in the body for weeks) and weaker anti-estrogen activity. Some research suggests it may partially offset enclomiphene's benefits, which is one reason a purified enclomiphene product was developed in the first place ^[2]. So when people ask whether enclomiphene and clomiphene are the same thing, the honest answer is: related, but not identical. Clomiphene is the whole mixture; enclomiphene is the more active half.

How does enclomiphene compare to TRT for fertility?

This is the question that actually matters for most men considering it. Exogenous testosterone (injections, gels, pellets) works by directly replacing what your testes aren't making. Your brain detects that testosterone level as "already high," so it shuts down LH and FSH signaling. No LH signal means the testes stop producing testosterone locally and stop supporting sperm production. Testicular volume shrinks over months, and sperm counts can drop to near zero in a large share of men on TRT ^[3]. Enclomiphene works upstream instead. Because it raises LH and FSH rather than suppressing them, the testes keep getting the signal to function. Multiple studies, including a 2013 clinical trial comparing enclomiphene to topical testosterone, found that enclomiphene raised total testosterone into the normal range while maintaining or increasing LH, FSH, and sperm parameters, whereas the testosterone gel group saw suppressed LH/FSH and sperm counts fall ^[4]. That is a real and meaningfully different mechanism, not marketing spin. But "tends to preserve fertility" is not the same as "guarantees fertility outcomes." Nobody has published a large randomized trial tracking live birth rates or long-term semen analysis over years of enclomiphene use. What exists is shorter-duration data (typically 3 to 6 months) showing preserved LH/FSH signaling and stable or improved sperm parameters compared to testosterone therapy ^{[4] [5]}. If you want the mechanism explained further with real before/after data points, see enclomiphene before and after.

Why isn't enclomiphene FDA-approved, and does that matter?

Here's the part a lot of sellers gloss over: enclomiphene citrate, under the brand name Androxal, went through Phase 3 clinical trials run by Repros Therapeutics between roughly 2009 and 2015, aiming for approval as a treatment for secondary hypogonadism in men. It never got approved. The FDA raised concerns, and Repros eventually stopped pursuing it after failing to reach agreement with the agency on further trial requirements ^[6]. That means every enclomiphene product sold in the US today is a compounded preparation, made by a licensed compounding pharmacy under Section 503A or 503B of the Food, Drug, and Cosmetic Act, not an FDA-approved drug with an established manufacturer, standardized dosing label, or post-market surveillance requirement ^[7]. Compounded drugs are legal and pharmacies are regulated by state boards of pharmacy and the FDA, but they don't go through the same efficacy and safety review as an approved NDA (New Drug Application) product. Does that matter practically? It cuts both ways. It means dosing isn't standardized the way, say, testosterone cypionate is, and potency can vary somewhat between compounding pharmacies. It also means insurance essentially never covers it. On the other hand, compounding lets prescribers use enclomiphene off-label based on the clinical judgment that its mechanism and existing trial data support a reasonable risk-benefit tradeoff for men who want testosterone support without shutting down fertility. If you're choosing a source, working with a clinician who prescribes through a provider-reviewed pathway and a named, accountable compounding pharmacy matters more here than it would with an approved generic.

What are the real pros of enclomiphene?

Fertility and testicular size preservation is the headline pro, and it's the one with actual comparative trial data behind it ^[4]. Men who want to have children later, or who don't want their testicles to shrink and their sperm count to crater while on hormone therapy, have a real alternative mechanism here that injectable or topical TRT doesn't offer. It's also an oral tablet, not a weekly injection, which some men genuinely prefer logistically. Because it stimulates your own production rather than replacing it, some men find their testosterone-to-estrogen ratio behaves more naturally, since the testes are still making the normal downstream hormones (more than testosterone) that come with intact Leydig cell function. And unlike TRT, stopping enclomiphene doesn't require a separate "restart protocol" the way shutting down years of exogenous testosterone often does, because the HPG axis was never shut off in the first place. Cost, relative to some branded TRT products, can be lower, though this varies a lot by pharmacy and dose. For men who respond well, testosterone increases in published data have moved men from the 200s-300s ng/dL range into the 500s-600s ng/dL range over 3 to 6 months ^{[4] [5]}, which is a meaningful clinical change, not a marginal one.

What are the real cons and risks of enclomiphene?

Start with the biggest one: it doesn't work the same for everyone. Response depends on your hypothalamic-pituitary-gonadal axis actually being capable of responding to increased signaling. Men with primary testicular failure (where the testes themselves can't respond to LH/FSH, regardless of how much signal arrives) won't benefit from enclomiphene the way men with secondary (hypothalamic/pituitary) hypogonadism do. If your low testosterone stems from a testicular problem rather than a signaling problem, enclomiphene is likely to underperform. Side effects reported in trials include visual disturbances (blurred vision, in rare cases), mood changes, headache, and in some men, testosterone levels that rise less than expected ^{[1] [4]}. Visual side effects are the one that gets specific FDA-level attention with the whole clomiphene class; the enclomiphene isomer was developed partly because it was thought to carry a better side effect profile than the zuclomiphene-containing mixture, but rare visual events have still shown up in trial reporting for related compounds ^[1]. Long-term safety data is genuinely thin. Most published enclomiphene studies run 3 to 6 months. Nobody has a 5-year or 10-year outcome dataset the way we do for testosterone replacement, so if you're asking "is this safe to stay on for a decade," the honest answer is that the evidence doesn't reach that far yet. Because it's compounded, quality and dosing consistency depend heavily on which pharmacy fills the prescription. And it requires a prescription and ongoing bloodwork, which means real clinical oversight, not a supplement you order and forget about.

Does enclomiphene actually preserve fertility, or is that overstated?

The honest answer is: it preserves the mechanism fertility depends on, more reliably than TRT does, but "preserves" isn't the same as "guarantees." In the 2013 comparative trial, men on enclomiphene maintained LH, FSH, and sperm concentration roughly at baseline or better, while men on transdermal testosterone gel saw significant drops in all three ^[4]. That is solid mechanistic and short-term evidence. It's also the primary reason clinicians reach for enclomiphene in men who are still trying to conceive, or who simply don't want to close that door. What's missing is large-scale, long-duration data tracking actual pregnancy or live birth rates in couples where the male partner used enclomiphene. That kind of trial is expensive and rare for any male fertility drug, more than this one. So when you see fertility framed as a "pro" of enclomiphene, it should be framed specifically: preserved sperm parameters and gonadotropin signaling in available studies, not a promised path to conception. If fertility preservation is your main reason for considering enclomiphene over TRT, that reasoning is well-supported by the mechanism and the comparative data that exists. Just don't treat it as a fertility treatment in the way clomiphene is sometimes prescribed for female infertility; treat it as a testosterone therapy option that doesn't foreclose fertility the way TRT does.

How does enclomiphene compare to clomiphene citrate directly?

What does the timeline and success rate actually look like?

In the published trials, meaningful testosterone increases typically showed up within 3 months, with continued stabilization by 6 months ^{[4] [5]}. That doesn't mean every man feels different by week 2; hormone-driven symptoms like energy, libido, and mood tend to lag the bloodwork changes. Not every man reaches an ideal range on enclomiphene alone. Response depends on baseline LH/FSH, the underlying cause of low testosterone, dose, and individual sensitivity. Some men need dose adjustments over the first two cycles of bloodwork before landing on an effective regimen. If you want the week-by-week expectations mapped out, enclomiphene first month what to expect and enclomiphene results timeline go through that in more detail. For a broader look at how often men actually reach their testosterone goals on it, see enclomiphene success rate.

Who is a good candidate for enclomiphene, and who isn't?

Good candidates tend to be men with secondary hypogonadism (low testosterone driven by low or inappropriately normal LH/FSH, not testicular damage), who want to preserve fertility or testicular size, and who are willing to do regular bloodwork to track response. Men actively trying to conceive, or planning to within the next year or two, are often the clearest fit given the mechanism. Poor candidates include men with primary testicular failure (elevated LH/FSH already, with testes unable to respond), men with a history of estrogen-receptor-sensitive conditions where anti-estrogen mechanisms carry more theoretical risk, and men who want the fastest, most predictable testosterone increase regardless of fertility, since injectable TRT generally produces more consistent, controllable levels. Men with a history of pituitary tumors, significant vision problems, or blood clotting disorders should have those flagged and discussed directly with a prescriber before starting, given the drug class's reporting history ^[1].

Is enclomiphene actually worth it compared to just doing TRT?

That depends entirely on what you're optimizing for. If fertility preservation and avoiding testicular atrophy are priorities, enclomiphene has a real mechanistic and short-term evidence advantage over TRT that no amount of TRT protocol tweaking (hCG add-on aside) fully replicates. If you want the most predictable, well-studied, insurance-covered path to normal testosterone and don't care about fertility, TRT has decades more outcome data, FDA-approved formulations, and more consistent lab response. Some men use hCG alongside TRT specifically to preserve testicular function, which is a reasonable middle path worth discussing with a prescriber, but it adds cost and complexity rather than removing it. For a fuller cost-benefit breakdown including price ranges and what actual patient-reported experiences look like, is enclomiphene worth it and enclomiphene reviews go deeper on that specific question. If you decide to move forward, working through a provider-reviewed pathway, like the one Enclomiphene Direct connects patients to, with bloodwork before and during treatment and a named, licensed compounding pharmacy fulfilling the prescription, is the way to do this safely rather than sourcing it from an unregulated source.

Frequently asked questions

Is enclomiphene the same as clomiphene?

No. Clomiphene citrate (Clomid) is a mixture of two isomers, enclomiphene and zuclomiphene. Enclomiphene is the more active isomer for raising testosterone in men; zuclomiphene has a much longer half-life and may partially blunt the benefit, which is why a purified enclomiphene product was developed separately ^[3].

Is enclomiphene FDA-approved?

No. Enclomiphene (developed as Androxal) went through Phase 3 trials for male hypogonadism but was never approved; the sponsor, Repros Therapeutics, discontinued the program after not reaching agreement with the FDA on further requirements ^[7]. Every enclomiphene product available today is compounded, not FDA-approved as a standalone drug.

Does enclomiphene really preserve fertility better than TRT?

Available trial data supports this: enclomiphene maintained LH, FSH, and sperm parameters while testosterone gel suppressed them in a 2013 comparative study ^[5]. That's solid short-term mechanistic evidence, but no large trial has tracked long-term pregnancy or live birth rates specifically in men using enclomiphene.

Can enclomiphene shrink your testicles like TRT can?

Testicular atrophy on TRT happens because exogenous testosterone suppresses LH/FSH signaling that keeps the testes active. Enclomiphene raises LH/FSH instead of suppressing it, so published studies show maintained or improved testicular function rather than atrophy ^[5]. It isn't risk-free, but the mechanism doesn't drive shrinkage the way TRT does.

How long does enclomiphene take to raise testosterone?

Clinical trial data shows meaningful testosterone increases within about 3 months of consistent dosing, with levels generally stabilizing by 6 months ^[5][6]. Individual response varies with baseline hormone levels, dose, and the underlying cause of low testosterone, so some men need dose adjustments during the first couple of bloodwork cycles.

What are the main side effects of enclomiphene?

Reported side effects in trials include headache, mood changes, and rare visual disturbances associated with the clomiphene drug class ^[2][5]. Long-term safety data beyond 6 months is limited, so ongoing monitoring with a prescriber and periodic bloodwork is the standard approach rather than treating it as a set-and-forget medication.

Who should not take enclomiphene?

Men with primary testicular failure (where testes can't respond to LH/FSH regardless of signal) typically don't benefit. Men with a history of pituitary tumors, significant vision problems, estrogen-receptor-sensitive conditions, or clotting disorders should discuss those specifically with a prescriber before starting, given reporting patterns in the clomiphene drug class ^[2].

Why is enclomiphene compounded instead of a regular prescription drug?

Because it never received FDA approval as a standalone product. The Androxal development program for enclomiphene stopped after Phase 3 trials without approval ^[7]. As a result, licensed compounding pharmacies prepare it under Section 503A/503B compounding rules, based on a prescriber's clinical judgment, rather than it being manufactured as an approved generic ^[8].

Does insurance cover enclomiphene?

Generally, no. Because it's a compounded medication rather than an FDA-approved drug, most insurance plans don't cover it, and men typically pay out of pocket. Costs vary by pharmacy and dose; a licensed provider working with a named compounding pharmacy can give you an accurate, current price.

Can women take enclomiphene?

Enclomiphene isn't approved or typically prescribed for women; clomiphene citrate (the enclomiphene/zuclomiphene mixture) is the FDA-approved drug for inducing ovulation in women with certain infertility conditions ^[1]. The two aren't interchangeable in practice, and enclomiphene alone hasn't gone through the same female-fertility trial program.

Is enclomiphene safer than testosterone injections?

"Safer" depends on what you're measuring. For fertility and testicular size, enclomiphene has a real mechanistic advantage. For long-term outcome data and dosing consistency, TRT has decades more history and FDA-approved formulations. Neither is risk-free, and the right choice depends on your priorities and a prescriber's assessment of your specific hormone pattern.

Does enclomiphene work for everyone with low testosterone?

No. It works best for secondary hypogonadism, where the problem is insufficient LH/FSH signaling rather than testicular damage. Men with primary testicular failure typically see little benefit, because the testes can't respond to increased signaling no matter how much LH and FSH enclomiphene helps produce.

Sources

1. FDA, Clomiphene citrate (Clomid) prescribing information: Clomiphene citrate is FDA-approved for inducing ovulation in women, not for male use
2. Kim et al., 'Enclomiphene for the treatment of secondary hypogonadism', Sexual Medicine Reviews: Zuclomiphene has a longer half-life and may partially offset enclomiphene's anti-estrogen benefit
3. Endocrine Society, Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism (2018): Exogenous testosterone therapy suppresses LH/FSH and can suppress spermatogenesis
4. Kaminetsky et al., 'Effects of enclomiphene citrate vs testosterone gel on total testosterone, sperm parameters and gonadotropins in men with secondary hypogonadism', Journal of Sexual Medicine (2013): Enclomiphene maintained or raised LH, FSH and sperm parameters while testosterone gel suppressed them
5. Wiehle et al., 'Enclomiphene citrate stimulates testosterone production while preventing oligospermia', Fertility and Sterility (2014): Enclomiphene raised testosterone into normal range over 3 to 6 months while preserving sperm counts
6. Repros Therapeutics, SEC Form 8-K disclosure on Androxal program discontinuation: Repros Therapeutics discontinued the Androxal (enclomiphene) approval program after failing to reach agreement with FDA
7. FDA, 'Human Drug Compounding' overview of Sections 503A and 503B of the FD&C Act: Compounded drugs like enclomiphene are prepared under Section 503A/503B rules rather than as FDA-approved manufactured drugs